The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis



Status:Recruiting
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - 95
Updated:12/16/2018
Start Date:January 2017
End Date:January 2020
Contact:Wael Jaber, MD
Email:JABERW@ccf.org
Phone:216 444-8305

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The investigators postulate that F-18 florbetapir will show improved detection of cardiac
amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

F-18 florbetapir is currently used for the early detection of brain amyloid (Alzheimer's
disease). The hypothesis is that F-18 florbetapir will detect amyloid deposition in
myocardium prior to current non-invasive diagnostic measures, particular electrocardiography
with strain and technetium pyrophosphate scintigraphy. The investigators intend to use F-18
florbetapir and assess its correlation between standard non-invasive diagnostic modalities.

Inclusion Criteria:

1. Patients with extra-cardiac biopsy-proven AL or ATTR amyloidosis

2. Patients with a ratio of affected to unaffected free light chains >5 or free light
chain difference of >50

Exclusion Criteria:

1. Echocardiographic evidence of cardiac amyloidosis with septal and posterior wall
thickness ≥ 13mm

2. Contraindication to florbetapir or its components

3. Refusal to participate in the study
We found this trial at
1
site
Cleveland Clinic Foundation (Main Campus)
9500 Euclid Avenue
Cleveland, Ohio 44195
Principal Investigator: Wael Jaber, M.D.
Phone: 216-444-8305
?
mi
from
Cleveland, OH
Click here to add this to my saved trials